1-11 of 11
Xinan Sheng
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma

Junru Chen, Xu Hu, Junjie Zhao, Xiaoxue Yin, Linmao Zheng, Jingjing Guo, Jianhui Chen, Yongquan Wang, Xinan Sheng, Haiying Dong, Xiaodong Liu, Xingming Zhang, Jiayu Liang, Haolin Liu, Jin Yao, Jiyan Liu, Yali Shen, Zhibin Chen, Zhengyu He, Yaodong Wang, Ni Chen, Ling Nie, Mengni Zhang, Xiuyi Pan, Yuntian Chen, Haoyang Liu, Yaowen Zhang, Yanfeng Tang, Sha Zhu, Jinge Zhao, Jindong Dai, Zilin Wang, Yuhao Zeng, Zhipeng Wang, Haojie Huang, Zhenhua Liu, Pengfei Shen, Hao Zeng, Guangxi Sun
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (11): 2571–2581.
https://doi.org/10.1158/1078-0432.CCR-23-2760
Published: 03 June 2024
View article titled, Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma
Open the PDF for Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

First-in-Human Study of the Radioligand 68Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma

Xiaojiang Duan, Lei Xia, Zhuochen Zhang, Yanan Ren, Martin G. Pomper, Steven P. Rowe, Xuesong Li, Nan Li, Ning Zhang, Hua Zhu, Zhi Yang, Xinan Sheng, Xing Yang
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (17): 3395–3407.
https://doi.org/10.1158/1078-0432.CCR-23-0609
Published: 01 September 2023
View article titled, First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
Open the PDF for First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma in another window
Includes: Multimedia, Supplementary data
Journal Articles

Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03

Xinan Sheng, Haige Chen, Bin Hu, Xudong Yao, Ziling Liu, Xin Yao, Hongqian Guo, Yi Hu, Zhigang Ji, Hong Luo, Benkang Shi, Jiyan Liu, Jin Wu, FangJian Zhou, Zhisong He, Jinhai Fan, Weifeng Wang, Hui Feng, Sheng Yao, Patricia Keegan, Yiran Huang, Jun Guo
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (3): 489–497.
https://doi.org/10.1158/1078-0432.CCR-21-2210
Published: 01 February 2022
View article titled, Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03
Open the PDF for Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03 in another window
Includes: Supplementary data
Journal Articles

Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Xinan Sheng, Xieqiao Yan, Lin Wang, Yanxia Shi, Xin Yao, Hong Luo, Benkang Shi, Jiyan Liu, Zhisong He, Guohua Yu, Jianming Ying, Weiqing Han, Changlu Hu, Yun Ling, Zhihong Chi, Chuanliang Cui, Lu Si, Jianmin Fang, Aiping Zhou, Jun Guo
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (1): 43–51.
https://doi.org/10.1158/1078-0432.CCR-20-2488
Published: 04 January 2021
View article titled, Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Open the PDF for Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma in another window
Includes: Supplementary data
Journal Articles

Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma

Jiayi Yu, Junya Yan, Qian Guo, Zhihong Chi, Bixia Tang, Bin Zheng, Jinyu Yu, Ting Yin, Zhiyuan Cheng, Xiaowen Wu, Huan Yu, Jie Dai, Xinan Sheng, Lu Si, Chuanliang Cui, Xue Bai, Lili Mao, Bin Lian, Xuan Wang, Xieqia Yan, Siming Li, Li Zhou, Keith T. Flaherty, Jun Guo, Yan Kong
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (21): 6511–6523.
https://doi.org/10.1158/1078-0432.CCR-19-0475
Published: 01 November 2019
View article titled, Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma
Open the PDF for Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma in another window
Includes: Supplementary data
Journal Articles

Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy

Yan Kong, Xinan Sheng, Xiaowen Wu, Junya Yan, Meng Ma, Jiayi Yu, Lu Si, Zhihong Chi, Chuanliang Cui, Jie Dai, Yiqian Li, Huan Yu, Tianxiao Xu, Huan Tang, Bixia Tang, Lili Mao, Bin Lian, Xuan Wang, Xieqiao Yan, Siming Li, Jun Guo
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (22): 6946–6957.
https://doi.org/10.1158/1078-0432.CCR-17-0070
Published: 14 November 2017
View article titled, Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy
Open the PDF for Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy in another window
Includes: Supplementary data
Journal Articles

MAPK Pathway and TERT Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases

Xue Bai, Yan Kong, Zhihong Chi, Xinan Sheng, Chuanliang Cui, Xuan Wang, Lili Mao, Bixia Tang, Siming Li, Bin Lian, Xieqiao Yan, Li Zhou, Jie Dai, Jun Guo, Lu Si
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (20): 6120–6127.
https://doi.org/10.1158/1078-0432.CCR-17-0980
Published: 12 October 2017
View article titled, <em>MAPK</em> Pathway and <em>TERT</em> Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases
Open the PDF for <em>MAPK</em> Pathway and <em>TERT</em> Promoter Gene Mutation Pattern and Its Prognostic Value in Melanoma Patients: A Retrospective Study of 2,793 Cases in another window
Includes: Supplementary data
Journal Articles

Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Yan Kong, Lu Si, Yiqian Li, Xiaowen Wu, Xiaowei Xu, Jie Dai, Huan Tang, Meng Ma, Zhihong Chi, Xinan Sheng, Chuanliang Cui, Jun Guo
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (4): 1018–1027.
https://doi.org/10.1158/1078-0432.CCR-15-1110
Published: 14 February 2016
View article titled, Analysis of <em>mTOR</em> Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors
Open the PDF for Analysis of <em>mTOR</em> Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors in another window
Includes: Supplementary data
Journal Articles

Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Jie Dai, Yan Kong, Lu Si, Zhihong Chi, Chuanliang Cui, Xinan Sheng, Lili Mao, Siming Li, Bin Lian, Ruifeng Yang, Shujing Liu, Xiaowei Xu, Jun Guo
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (24): 6935–6942.
https://doi.org/10.1158/1078-0432.CCR-13-1266
Published: 16 December 2013
View article titled, Large-scale Analysis of <em>PDGFRA</em> Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib
Open the PDF for Large-scale Analysis of <em>PDGFRA</em> Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib in another window
Includes: Supplementary data
Journal Articles

Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma

Bin Lian, Lu Si, Chuanliang Cui, Zhihong Chi, Xinan Sheng, Lili Mao, Siming Li, Yan Kong, Bixia Tang, Jun Guo
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (16): 4488–4498.
https://doi.org/10.1158/1078-0432.CCR-13-0739
Published: 13 August 2013
View article titled, Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma
Open the PDF for Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma in another window
Includes: Supplementary data
Journal Articles

Large-Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma

Yan Kong, Lu Si, Yanyan Zhu, Xiaowei Xu, Christopher L. Corless, Keith T. Flaherty, Li Li, Haifu Li, Xinan Sheng, Chuanliang Cui, Zhihong Chi, Siming Li, Mei Han, Lili Mao, Aiping Lu, Jun Guo
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (7): 1684–1691.
https://doi.org/10.1158/1078-0432.CCR-10-2346
Published: 31 March 2011
View article titled, Large-Scale Analysis of <em>KIT</em> Aberrations in Chinese Patients with Melanoma
Open the PDF for Large-Scale Analysis of <em>KIT</em> Aberrations in Chinese Patients with Melanoma in another window
Includes: Supplementary data